Literature DB >> 30768228

Topical Aqueous Suppression and Closure of Idiopathic Full-Thickness Macular Holes.

Daniel Su, Anthony Obeid, Jason Hsu.   

Abstract

Hydration of retinal tissue has been proposed as a potential model of macular hole (MH) formation in addition to tractional forces of the vitreous and internal limiting membrane (ILM). Carbonic anhydrase inhibitors have previously been utilized in the treatment of cystoid macular edema in outer retinal diseases. There has been recent interest in the use of topical aqueous suppression as a potential medical therapy for MHs. In this case series, four eyes with small (< 300 μm) full-thickness MHs were treated with topical dorzolamide-timolol for 1 month. Two eyes achieved closure of the MH without surgical intervention, whereas the other two required pars plana vitrectomy with ILM peel. Future studies are required to investigate the role of topical aqueous suppression in the management of MHs. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e38-e43.]. Copyright 2019, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30768228     DOI: 10.3928/23258160-20190129-17

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  3 in total

1.  Full-thickness macular holes after surgical repair of primary rhegmatogenous retinal detachments: incidence, clinical characteristics, and outcomes.

Authors:  Matthew R Starr; Crystal Lee; Diego Arias; Raziyeh Mahmoudzadeh; Mirataollah Salabati; Ajay E Kuriyan; Carl D Regillo; Jason Hsu; Yoshihiro Yonekawa; Omesh P Gupta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-21       Impact factor: 3.117

2.  Intentional use of topical latanoprost with resulting macular edema to help in the closure of a failed, chronic, macular hole.

Authors:  H Logan Brooks; Cuneyt Ozkardes
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-08

3.  Successful Treatment of Full-Thickness Macular Hole in Polypoidal Choroidal Vasculopathy with Anti-VEGF Therapy.

Authors:  Aaron Lindeke-Myers; Gregg T Kokame; Steven Yeh; Jessica Shantha
Journal:  J Vitreoretin Dis       Date:  2020-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.